Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (1319)	3/15/2007 10:21:00 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 3661

DDD down 50% AP Wyeth Ends License Agreement With SCOLR Thursday March 15, 10:17 am ET SCOLR Pharma Collaboration With Wyeth Over Extended Release Ibuprofen Ends; Shares Plunge BELLEVUE, Wash. (AP) -- Drug developer SCOLR Pharma Inc. said Thursday Wyeth is ending its licensing agreement for SCOLR'S technology in products with ibuprofen, sending its shares plummeting. SCOLR said it will either look for another partner to develop its 12-hour extended release ibuprofen or work on the drug itself. The companies signed the development and license agreement Dec. 21, 2005 and SCOLR has already received $2.1 million in milestone and other payments. The licensing agreement will end effective April 16 and all rights to the technology for ibuprofen products goes back to SCOLR. Shares of SCOLR shed $1.45, or 43 percent, to $1.87 in morning trading on the American Stock Exchange. Over the past 52 weeks, the stock has ranged between $3.10 and $7.05, and is down nearly 29 percent year-to-date